Nuformix plc (LON:NFX) Executive Director Dr. Dan Gooding caught up with DirectorsTalk for an exclusive interview to discuss recent patents for NXP002 & NXP004, highlights from interim results, and what’s
Nuformix Plc (LON:NFX), a pharmaceutical development company focused on drug repurposing for fibrosis and oncology, recently provided a patent update for its NXP002 and NXP004 programs, as well as its interim
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the six months ended 31 March 2024. Operational highlights
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its audited results for the eighteen months ended 30 September 2023 following the
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company has achieved the second milestone according to its updated
Nuformix plc (LON: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that it has been issued with an Official Decision to Grant
Nuformix’s Dan Gooding discusses the revised agreement with Oxilio for NXP001 and the progress on NXP002 & NXP004 in this exclusive interview with DirectorsTalk.
Nuformix plc (LON:NFX) Executive Director Dan Gooding joins DirectorsTalk to discuss an update on its NXP001 exclusive licensing agreement. In this interview Dr Dan Gooding outlines what the revised agreement covers,
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company is to receive new immediate and near-term undisclosed milestone
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
